FLACS is related to an increase of anterior chamber prostaglandin and cytokines, resulting in intra-operative miosis. This can be prevented by pre-operative non-steroidal anti-inflammatory drug application. As a result of methodological problems, several studies on the association between femtosecond laser-assisted cataract surgery and cystoid macular oedema are inconclusive.
FLACS is related to an increase of anterior chamber prostaglandin and cytokines, resulting in intra-operative miosis. This can be prevented by pre-operative non-steroidal anti-inflammatory drug application. As a result of methodological problems, several studies on the association between femtosecond laser-assisted cataract surgery and cystoid macular oedema are inconclusive.
Diabetes mellitus is a common health problem in developed countries, with diabetic macular oedema (DMO) being a major cause of visual loss. A variety of treatment modalities for DMO are available including laser, steroid and intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.
Idiopathic macular telangiectasia (MacTel) is bilateral condition characterised by ectatic capillaries of the macula and atrophy of the neurosensory retina. Familiarity with the distinctive intraretinal cavitation on SD-OCT in type 2, the most common type, is key for correct diagnosis.
Diabetes mellitus is a common health problem in developed countries, with diabetic macular oedema (DMO) being a major cause of visual loss. A variety of treatment modalities for DMO are available including laser, steroid and intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.
Prevent Blindness dedicates the third week of May to raising awareness of the benefit of genetic testing, variety of retinal diseases, and available resources.
As we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
Study evaluates the impact of surgical procedure on visual outcomes in patients
Despite its status as an essential postoperative safety eye product and its utilization by every ocular surgeon with every ocular surgery, eye shield innovation has been neglected to date.
The Ophthalmic World Leaders (OWL) Leadership Summit, scheduled for September 21 and 22, 2023, in Austin, Texas, will feature a lineup of prominent speakers and engaging discussions on a wide range of leadership topics and industry insights.
Study of subjects with rare inherited form of AD shows increased retinal capillary perfusion during the presymptomatic stage.
The prosthesis bypasses the optic nerve and sends images directly to the patient's brain to create artificial sight.
According to physician, this therapeutic may prove to be a treatment option for these diseases.
‘From the Bench to Bedside and Back’ is focal point for this year’s conference
Face-down positioning is associated with a reduction in certain complications following macula-involving retinal displacement (RD) repair, according to researchers.
Topline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
With 37 years of clinical trial experience, Peter J. McDonnell, MD, offer some tips.
Improvement in visual acuity, central retinal thickness, vitreous haze reported at 6 months
A mutation-agnostic optogenetic gene therapy is in development using multi-characteristic opsin (MCO) to sensitize the retinal bipolar cells to detect light.
Survey respondents point to a perceived gap in treatments for uveitic macular edema, document interest in suprachoroidal drug delivery.
As we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
The FDA has approved changes to the drug label of the anti-seizure drug ezogabine (Potiga), underscoring risks of abnormalities to the retina in the eye, potential vision loss, and skin discoloration-all of which may become permanent.
Optical coherence tomography angiography can detect microcirculatory disturbances during acute attacks.
Among a subset of patients in the phase IV PALADIN study, there was improved visual acuity, improved macular thickness, and reduced treatment burden among patients treated with the intravitreal fluocinolone acetonide 0.2 µg (Iluvien implant) for DME.
A study has revealed that a budgetary saving per treated patient with the fluocinolone acetonide implant (Iluvien) versus ranibizumab (Lucentis) could lead to a significant cost-saving to NHS England.
Preliminary research has shown that ataluren is effective in overriding the nonsense mutation in choroideremia patients, however, further research is needed.
A retina specialist discusses impressions and key take away points from patient case.